{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:17:27Z","timestamp":1791778647238,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.jpba.2011.10.003","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T23:01:14Z","timestamp":1318892474000},"page":"109-116","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["HPLC\u2013MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)"],"prefix":"10.1016","volume":"59","author":[{"given":"Antonio","family":"D\u2019Avolio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Simiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"De Francia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ariaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Baietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2011.10.003_bib0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2011.10.003_bib0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2011.10.003_bib0015","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0731-7085(02)00080-8","article-title":"Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography\u2013tandem mass spectrometry","volume":"28","author":"Bakhtiar","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2011.10.003_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as a paradigm of targeted therapies","volume":"91","author":"Druker","year":"2004","journal-title":"Adv. Cancer. Res."},{"key":"10.1016\/j.jpba.2011.10.003_bib0025","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2011.10.003_bib0030","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2011.10.003_bib0035","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2011.10.003_bib0040","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2011.10.003_bib0045","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jpba.2011.10.003_bib0050","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","article-title":"Mechanisms of resistance to STI571 in philadelphia chromosome-associated leukemias","volume":"22","author":"Shah","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jpba.2011.10.003_bib0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL","volume":"61","author":"Kamath","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2011.10.003_bib0060","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2011.10.003_bib0065","first-page":"114","article-title":"Src in cancer: deregulation and consequences for cell behaviour","volume":"1602","author":"Frame","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jpba.2011.10.003_bib0070","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2011.10.003_bib0075","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2011.10.003_bib0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jpba.2011.10.003_bib0085","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2011.10.003_bib0090","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2011.10.003_bib0095","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2011.10.003_bib0100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2011.10.003_bib0105","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","article-title":"Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders","volume":"65","author":"Singh","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2011.10.003_bib0110","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.leukres.2009.08.005","article-title":"Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography\u2013ultraviolet detection and liquid chromatography\u2013tandem mass spectrometry: methods\u2019 comparison","volume":"34","author":"Awidi","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jpba.2011.10.003_bib0115","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","article-title":"Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC\/MS\u2013MS","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2011.10.003_bib0120","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.leukres.2009.11.009","article-title":"Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography","volume":"34","author":"Davies","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jpba.2011.10.003_bib0125","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","article-title":"New HPLC\u2013MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma","volume":"877","author":"De Francia","year":"2009","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2011.10.003_bib0130","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/bmc.1247","article-title":"Development and validation of a sensitive assay for the quantification of imatinib using LC\/LC\u2013MS\/MS in human whole blood and cell culture","volume":"23","author":"Klawitter","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2011.10.003_bib0135","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.cca.2010.08.014","article-title":"Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma","volume":"411","author":"Micova","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2011.10.003_bib0140","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/bmc.1364","article-title":"High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma","volume":"24","author":"Miura","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2011.10.003_bib0145","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/chromsci\/49.5.412","article-title":"Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection","volume":"49","author":"Miura","year":"2011","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2011.10.003_bib0150","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/bmc.816","article-title":"Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography","volume":"21","author":"Oostendorp","year":"2007","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2011.10.003_bib0155","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jchromb.2009.05.034","article-title":"A high-performance liquid chromatography\u2013mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum","volume":"877","author":"Parise","year":"2009","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2011.10.003_bib0160","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jchromb.2007.01.019","article-title":"High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations","volume":"852","author":"Pursche","year":"2007","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2011.10.003_bib0165","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cca.2009.10.007","article-title":"Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC\u2013MS\/MS","volume":"411","author":"Roth","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2011.10.003_bib0170","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","article-title":"Quantification of imatinib in human plasma by high-performance liquid chromatography\u2013tandem mass spectrometry","volume":"27","author":"Titier","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2011.10.003_bib0175","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1248\/bpb.34.1126","article-title":"High-performance liquid chromatographic assay for the determination of nilotinib in human plasma","volume":"34","author":"Yuki","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jpba.2011.10.003_bib0180","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.leukres.2010.07.014","article-title":"Relationship of serum imatinib trough level and response in CML patients: long term follow-up","volume":"34","author":"Awidi","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jpba.2011.10.003_bib0185","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s12185-010-0576-y","volume":"91","author":"Faber","year":"2010","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.jpba.2011.10.003_bib0190","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2011.10.003_bib0195","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2011.10.003_bib0200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-009-0008-0","article-title":"Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme","volume":"97","author":"Holdhoff","year":"2010","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.jpba.2011.10.003_bib0205","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1016\/j.jchromb.2009.10.008","article-title":"Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib","volume":"877","author":"Roche","year":"2009","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2011.10.003_bib0210","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1248\/bpb.34.114","article-title":"Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia","volume":"34","author":"Nambu","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jpba.2011.10.003_bib0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jchromb.2005.02.010","article-title":"Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry","volume":"819","author":"Colombo","year":"2005","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2011.10.003_bib0220","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jpba.2010.10.011","article-title":"A HPLC\u2013MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation","volume":"54","author":"D\u2019Avolio","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2011.10.003_bib0225","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jac\/dkh487","article-title":"The intracellular pharmacology of antiretroviral protease inhibitors","volume":"54","author":"Ford","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2011.10.003_bib0230","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1128\/AAC.46.10.3228-3235.2002","article-title":"Intracellular accumulation of human immunodeficiency virus protease inhibitors","volume":"46","author":"Khoo","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2011.10.003_bib0235","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1128\/AAC.01236-10","article-title":"Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations","volume":"55","author":"Simiele","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2011.10.003_bib0240","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinbiochem.2004.11.007","article-title":"Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray\u2013tandem mass spectrometry","volume":"38","author":"Taylor","year":"2005","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2011.10.003_bib0245","series-title":"Guidance for Industry Bioanalytical Method Validation","author":"FDA","year":"2001"},{"key":"10.1016\/j.jpba.2011.10.003_bib0250","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1570-0232(01)00611-0","article-title":"High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography\u2013tandem mass spectrometry","volume":"768","author":"Bakhtiar","year":"2002","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2011.10.003_bib0255","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2011.10.003_bib0260","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jpba.2011.10.003_bib0265","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00216-009-3263-1","article-title":"Development and validation of a simultaneous extraction procedure for HPLC\u2013MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma","volume":"396","author":"Baietto","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2011.10.003_bib0270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/FTD.0b013e31819476fa","article-title":"Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV","volume":"31","author":"Baietto","year":"2009","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.jpba.2011.10.003_bib0275","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/AAC.01807-09","article-title":"Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma","volume":"54","author":"Baietto","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2011.10.003_bib0280","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/FTD.0b013e318189596d","article-title":"An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients","volume":"30","author":"D\u2019Avolio","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2011.10.003_bib0285","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jchromb.2006.10.030","article-title":"A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method","volume":"848","author":"D\u2019Avolio","year":"2007","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2011.10.003_bib0290","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchromb.2007.10.003","article-title":"HPLC\u2013MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients","volume":"859","author":"D\u2019Avolio","year":"2007","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2011.10.003_bib0295","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e3181cacbd0","article-title":"A validated high-performance liquid chromatography\u2013ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients","volume":"32","author":"D\u2019Avolio","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2011.10.003_bib0300","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jpba.2010.02.026","article-title":"HPLC\u2013MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions","volume":"52","author":"D\u2019Avolio","year":"2010","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708511005796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708511005796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T03:38:31Z","timestamp":1593142711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708511005796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":60,"alternative-id":["S0731708511005796"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2011.10.003","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}